Sleep health company SleepScore Labs reported on Tuesday the completion of the acquisition of Sleep.ai and its wearable and digital app that detects snoring and bruxism.
Sleep.ai is a digital health company specialised in highly sophisticated analysis during sleep using a mobile device. The apps use special algorithms to filter and detect snoring. It offers a CE-certified app specialised in detecting teeth grinding during sleep. The app gives the option to track progress over time, and if needed, can recommend a local medical professional if the condition is of concern. Sleep.ai reportedly created an app and wearable for detecting if a user is snoring and/or grinding their teeth, known as bruxism and helps dentists monitor patients after they've begun dental treatment for either condition.
Additionally, the Sleep.ai app has been downloaded more than 250,000 times from the App Store and Google Play store and Sleep.ai apps will still be available on its own website as well as SleepScore Labs'.
Following closing, Sleep.ai's founder and CEO Michiel Allessie, a Dutch board-certified sleep dentist, will join the SleepScore Labs team in Carlsbad, Calif., as vice president of Snoring and Bruxism to continue advancing the latest technologies in detecting sleep issues.
The terms of the acquisition were not disclosed by the companies.
Airiver medical receives FDA approval for central airway stenosis trial
Talphera reaches enrollment milestone in NEPHRO CRRT pivotal trial
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
Covalon Technologies secures DTC eligibility to expand US investor access
Navamedic ASA secures final approvals for Flexilev in OraFID across Nordic markets
Oncopeptides partners with SD Pharma to expand Pepaxti access in Spain
Aptar launches bio-based nasal spray pump with Haleon's Otrivin brand
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Predictmedix AI launches mobile diabetes screening platform in India
Navamedic's medical device OraFID approved as primary package for a pharmaceutical product
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions